Amarantus Bioscience Holdings Inc (AMBS)

[JJAAMMAANN]

Did I miss a PR stating that the Phase 2B studies have commenced on both LID and ADHD?

That and the fact that his first mentioned company mentioned under Freqent and intensive interactions is...get ready Blackhawks...Novartis! Could that be a coincidence???

DL: Yes. But let me add that we also have frequent and intensive interactions with large pharmaceutical companies working in the neuroscience area. That actually complements what we do on the private, micro-, small- and mid-cap fronts. We don’t work directly for large pharmas like Novartis AG (NVS:NYSE), Roche Holding AG (RHHBY:OTCQX), Sanofi SA (SNY:NYSE) or Eli Lilly and Co. (LLY:NYSE), but we definitely know what’s going on, and we know the right people to contact in those organizations about any particular R&D or business development opportunity.

We also know what’s going on in the in-licensing arena, which has been useful in the case of Amarantus BioScience. We helped to find the eltoprazine molecule that the company licensed; the molecule is now in Phase 2b for Parkinson’s disease levodopa-induced dyskinesia (PD-LID), as well as attention-deficit hyperactivity disorder (ADHD). Amarantus CEO Gerald Commissiong led the charge on the negotiation front and did a brilliant job.

http://jutiagroup.com/20140326-from-lab-bench-to-bedside-david-lowe-brings-common-sense-to-neuroscience-investing/" rel="nofollow" target="_blank" >http://jutiagroup.com/20140326-from-lab-bench-to-bedside-david-lowe-brings-common-sense-to-neuroscience-investing/

Awesome, Awesome, Awesome!
Time for the Carpet Bombing of Great News to Commence!
In my own Opinion of Course!
Long AMBS!